Geode Capital Management LLC Raises Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Geode Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 68.7% during the third quarter, HoldingsChannel reports. The firm owned 56,597 shares of the company’s stock after purchasing an additional 23,058 shares during the quarter. Geode Capital Management LLC’s holdings in Centessa Pharmaceuticals were worth $905,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in CNTA. Jane Street Group LLC acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $2,834,000. Wellington Management Group LLP acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $1,609,000. Nantahala Capital Management LLC acquired a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at $4,064,000. Ally Bridge Group NY LLC acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $4,951,000. Finally, Driehaus Capital Management LLC increased its holdings in Centessa Pharmaceuticals by 89.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after purchasing an additional 987,997 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insider Buying and Selling

In other news, CEO Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $15.32, for a total transaction of $39,709.44. Following the sale, the chief executive officer now directly owns 630,661 shares in the company, valued at approximately $9,661,726.52. The trade was a 0.41 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $15.38, for a total transaction of $180,591.96. Following the sale, the insider now owns 183,266 shares in the company, valued at approximately $2,818,631.08. This trade represents a 6.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 368,023 shares of company stock worth $6,335,574 in the last quarter. 11.59% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on CNTA shares. B. Riley started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective for the company. BMO Capital Markets upped their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday. They issued a “buy” rating for the company. Guggenheim increased their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Trading Down 2.9 %

Centessa Pharmaceuticals stock opened at $15.64 on Friday. The firm’s 50 day moving average price is $16.97 and its two-hundred day moving average price is $14.37. Centessa Pharmaceuticals plc has a 1 year low of $6.65 and a 1 year high of $18.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -10.22 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.